Alzheimer's Blood Test Social Media Misinformation Study
Analysis based on 6 articles · First reported Sep 16, 2026 · Last updated Sep 22, 2026
The study highlights regulatory and reputational risks for social media platforms Meta Platforms, Meta Platforms — Instagram and ByteDance — TikTok Shop regarding health misinformation, potentially inviting stricter oversight. For the diagnostics and healthcare sector, the findings may temper near-term enthusiasm for direct-to-consumer Alzheimer's blood testing while reinforcing the need for clinical oversight, with limited immediate effect on broader markets.
Researchers from University of Sydney published the first study of its kind examining how Alzheimer's disease blood tests are promoted on social media. The study, published in the Journal of the American Geriatrics Society, analyzed 188 posts shared between March 2014 and May 2025 on Meta Platforms, Meta Platforms — Instagram and ByteDance — TikTok Shop, reaching a combined audience of more than 114 million followers. The analysis found that more than a third of posts suggested the tests could be used to screen healthy people without symptoms of cognitive decline, despite current recommendations against routine testing of asymptomatic people. Only 36 percent of posts included evidence supporting their claims, and fewer than one quarter of those cited a specific study. Accounts with explicit financial interests were more than three times as likely to promote testing for people without symptoms. Lead author Jenna Smith from University of Sydney's School of Public Health and the Sydney Health Literacy Lab raised concerns that social media excitement can outpace the evidence, and warned that a positive result may create anxiety and uncertainty, particularly when there is no cure for Alzheimer's disease. The blood tests have been allowed in Australia since July this year. The Alzheimer s Association most recently updated standards for blood-based biomarker testing in 2024, specifying that tests should only be performed under clinician supervision and not on asymptomatic people. The researchers called for improved regulatory enforcement and resources to support conversations about the benefits, limitations and uncertainties surrounding testing.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard